U.S., April 8 -- ClinicalTrials.gov registry received information related to the study (NCT07513857) titled 'Trial of JYB1904 Injection in Adolescent Participants' on March 27.

Brief Summary: This Phase Ib Trial is Meant to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity Profiles of JYB1904 Injection in Adolescent Participants With Allergic Diseases.

Study Start Date: May 17

Study Type: INTERVENTIONAL

Condition: Allergic Diseases

Intervention: DRUG: JYB1904

Received a single 300 mg JYB1904 injection administered subcutaneously(SC) at D1

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Jemincare

Published by HT Digital Content Services with permission from Health Daily Digest....